# Table S2. Randomization of household compounds, and exclusion of compounds and household members

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Total** | **Phase 1** | **Phase 2** | **Phase 3** |
|  | Intervention | Control | Intervention | Control | Intervention | Control | Intervention | Control |
| **Number of household compounds randomized** | 195 | 186 | 22 | 18 | 69 | 65 | 104 | 103 |
| **Number of household compounds remaining after withdrawals / exclusions after randomization\* (explanation in footnote)** | 193 / 195(99%) | 184/186(99%) | 22/22(100%) | 18/18(100%) | 69/69(100%) | 63/65(97%) | 102/104(98%) | 103/103(100%) |
| **Number of household compound members enumerated in compounds after removal of withdrawn / excluded compounds (not including index case-patient)** | 1814 | 1607 | 184 | 178 | 617 | 479 | 1013 | 950 |
| **Number of compound members with fever at enrollment** | 78 / 1814(4%) | 53/1607(3%) | 0/184(0%) | 0/178(0%) | 66/617(11%) | 46/479(10%) | 12/1013(1%) | 7/950(1%) |
| **Number of susceptible compound members** | 1736 / 1814 (96%) | 1554/1607(97%) | 184/184(100%) | 178/178(100%) | 551/617(89%) | 433/479(90%) | 1001/1013(99%) | 943/950(99%) |
| **Number of susceptible compound members without syndromic surveillance data** | 75/1736(4%) | 56/1554(4%) | 5/184(3%) | 2/178(1%) | 3/551(1%) | 1/433(0%) | 67/1001(7%) | 53/943(6%) |
| **Number of susceptible compound members with syndromic surveillance information for >1 days** | 1661/1736(96%) | 1498/1554(96%) | 179/184(97%) | 176/178(99%) | 548/551(99%) | 432/433(100%) | 934/1001(93%) | 890/943(94%) |
| **Number of susceptible members in index case-patient households** | 863/1661(52%) | 727/1498(49%) | 95/179(53%) | 89/176(51%) | 284/548(52%) | 224/432(52%) | 484/934(52%) | 414/890(47%) |
| **Number of susceptible members in other households** | 798/1661(48%) | 771/1498(51%) | 84/179(47%) | 87/176(49%) | 264/548(48%) | 208/432(48%) | 450/934(48%) | 476/890(53%) |
|  |  |  |  |  |  |  |  |  |
| **Number of index case-patients with PCR-confirmed influenza (% of total randomized)** | 24/193(12%) | 36/184(20%) | 2/22(9%) | 3/18(17%) | 11/69(16%) | 17/63(27%) | 11/102(11%) | 16/103(16%) |
| **Number of susceptible members in compounds of index case-patients with PCR-confirmed influenza** | 177/1661(11%) | 250/1498(17%) | 15/179(8%) | 39/176(22%) | 77/548(14%) | 105/432(24%) | 85/934(9%) | 106/890(12%) |

\*excluded compounds that had travel time > 2 hours (# 1009), the compound withdrew from the study (# 3119), index case-patient was not present for > 3 days (# 2124 – removed because hh members not susceptible if index case-patient not present), and one compound was found to have fever among a member of the index case-patient household (4020 - intervention)